Home
Resources
Diseases
COVID-19
Hepatitis B
Human papillomavirus (HPV)
Malaria
Measles
Mpox
Pneumococcal disease
RSV (Respiratory syncytial virus)
Compendium
Hexavalent vaccines
HPV vaccines
Malaria vaccines
PCV vaccines
RSV vaccines
Training
Vaccine Portfolio Optimization and Prioritization (VPOP)
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (40)
NITAG documentation (1641)
Reports (63)
SAGE documentation (226)
Scientific publications (122)
Systematic reviews (SYSVAC) (3100)
Regions
Africa (297)
Americas (794)
Eastern Mediterranean (58)
Europe (744)
Global (1)
South-East Asia (82)
Western Pacific (216)
Diseases
Chikungunya (13)
Cholera (35)
COVID-19 (1589)
Cytomegalovirus (1)
Dengue (43)
Diphtheria (90)
Ebola (19)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (71)
Hepatitis A (69)
Hepatitis B (171)
Hepatitis C (5)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (77)
HIV / AIDS (10)
Human papillomavirus (HPV) (537)
Influenza (629)
Japanese encephalitis (34)
Lyme disease, Borreliosis (2)
Malaria (33)
Measles (144)
Meningococcal disease (155)
Moraxella catarrhalis (1)
Mpox (58)
Mumps (50)
Pertussis (120)
Pneumococcal disease (305)
Poliomyelitis (94)
Q fever (1)
Rabies (33)
Rotavirus (121)
RSV (Respiratory syncytial virus) (69)
Rubella (69)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (71)
Tick-borne encephalitis (14)
Tuberculosis (83)
Typhoid (32)
Varicella (77)
Yellow fever (44)
Zika (1)
Show more
5192 results found
2022
∙
ACIP
ACIP Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines
2022
∙
ACIP
ACIP Update to the Evidence to Recommendations for a Pfizer-BioNTech COVID-19 Booster in Children Ages 5-11 Years
2022
∙
UNITAG
Advisory Report on the Introduction of More WHO Approved Covid-19 Vaccines In Uganda
2022
∙
ATAGI
ATAGI recommendations for use of Pfizer COVID-19 vaccine as a booster dose in adolescents aged 16-17 years
2022
∙
ATAGI
ATAGI recommendations on the use of a booster dose of COVID-19 vaccine
2022
∙
ATAGI
ATAGI statement on defining 'up-to-date' status for COVID-19 vaccination
2022
∙
ATAGI
ATAGI statement on recommendations on a winter booster dose of COVID-19 vaccine
2022
∙
ATAGI
ATAGI updated recommendations for a winter dose of COVID-19 vaccine
2022
∙
Conseil Supérieur de la Santé (CSS)
Booster vaccination for children and adolescents
2022
∙
Conseil Supérieur de la Santé (CSS)
Booster vaccination for immunocompromised patients
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register
